The effect of low-dose esketamine on maternal depression after cesarean delivery

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400080617

Enrollment

Unknown

Registered

2024-02-02

Start date

2024-03-01

Completion date

Unknown

Last updated

2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postpartum depression

Interventions

A:Intravenous administration of ESketamine after delivery of the fetus (Jiangsu Hengrui Co., LTD., batch number: 201022BL) 0.125mg/kg diluted to 10ml, the postoperative intravenous analgesia pump 0.5m

B:Intravenous administration of ESketamine after delivery of the fetus (Jiangsu Hengrui Co., LTD., batch number: 201022BL) 0.125mg/kg diluted to 10ml, postoperative analgesia pump plus esketamine 1mg/

C:Intravenous administration of ESketamine after delivery of the fetus (Jiangsu Hengrui Co., LTD., batch number: 201022BL) 0.25mg/kg diluted to 10ml, postoperative intravenous analgesia pump 0.5mg/kg

D:Intravenous administration of ESketamine after delivery of the fetus (Jiangsu Hengrui Co., LTD., batch number: 201022BL) 0.25mg/kg diluted to 10ml, postoperative analgesia pump plus esketamine 1mg/k

E: In the control group, esketamine was not used. After delivery, the fetus was given 10ml of normal saline intravenically. Conventional postoperative intravenous analgesia pump 0.5mg/kg of nalbuphin

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1, age 20-50 years old; 2. ASAI-II level; 3. Gestation > 28 weeks; 4. Require postoperative analgesia treatment; 5. Cesarean section was performed in our hospital; 6. Agree to participate in this study and sign the agreement

Exclusion criteria

Exclusion criteria: 1. Refuse to participate in this study; 2, accompanied by serious cardiovascular and cerebrovascular diseases, serious liver and kidney dysfunction and other important organ failure; 3, opioid, sedative hypnosis, psychotropic drugs allergy or history of drug abuse: 4, communication disorders or mental disabilities; 5. The researcher believes that it is not suitable for this clinical researcher

Design outcomes

Primary

Measure	Time frame
EPDS;	—

Secondary

Measure	Time frame
Pittsburgh Sleep Quality Index, PSQI;Vital signs;Numeric Rating Scale (NRS) for pain ;PCA frequency of postoperative analgesia pump;	—

Countries

China

Contacts

Public ContactBinrong Wang

Xi 'an International Medical Center Hospital

549676914@qq.com+86 136 5928 9992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026